Обоснование границ признания эквивалентности показателей качества, безопасности и эффективности при разработке биоаналогов
Аннотация
Ключевые слова
Полный текст:
PDFЛитература
US FDA (2014). Immunogenicity Assessment for Therapeutic Protein Products.
EMA (2013). Remsima : EPAR - Public assessment report.
EMA (2008). Immunogenicity assessment of biotechnology-derived therapeutic proteins.
D. Ghaderi, R. E. Taylor, V. Padler-Karavani, et al., Nat Biotechnol., 28(8), 863 – 867 (2010).
EMA (2014). Similar biological medicinal products.
42 U. S. C § 262(k).
S. C. Chow and J. P. Liu, Design and Analysis of Bioavailability and Bioequivalence Studies, Chapman and Hall/CRC Press/Taylor & Francis Group, New York (2008).
EMA (2010). Investigation of bioequivalence.
US FDA (2003). Bioavailability and Bioequivalence Studies for Orally Administered Drug Products — General Considerations.
А. Н. Миронов, А. Н. Васильев, Е. В. Гавришина, Р. Р. Ниязов, Ремедиум, 10, 8 – 17 (2013).
А. Н. Миронов, А. Н. Васильев, Е. В. Гавришина и др., Consilium Med., 2, 78 – 84 (2014).
US FDA (2014). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), 34th ed.
B. M. Davit, D. P. Conner, B. Fabian-Fritsch, Am. Assoc. Pharm. Sci J., 10(1), 148–156 (2008).
X. Yu. Lawrence, Quality and Bioequivalence Standards for Narrow Therapeutic Index Drugs, US FDA (2011).
ICH (2009). Pharmaceutical Development, Q8(R2).
M. N. Cayen, Drug discovery and early drug development, In: Early Drug Development: Strategies and Routes to First-in-Human Trials, M. N. Cayen (ed.) , John Wiley & Sons, Inc., Hoboken, NJ (2010), pp. 3 – 24.
J. Visser, I. Feuerstein, T. Stangler, et al., BioDrugs, 27, 495 – 507 (2013).
ICH (2008). Pharmaceutical Quality System, Q10.
S. D. Roger, Nephrology, 11, 341 – 346 (2006).
J. Woodcock, J. Nat. Rev. Drug Discov., 6, 437 – 442 (2007).
S. C. Chow and J. P. Liu, J. Biopharm. Stat., 20, 10 – 30 (2010).
EMA Similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues (2014).
ICH (2005). Quality Risk Management, Q9.
ICH (2008). Pharmaceutical Quality System, Q10.
Al da Silva, U. Kronthaler, V. Koppenburg, et al., Leuk Lymphoma, 55(7), 1609 – 1617(2014); doi: 10.3109/10428194.2013. 843090.
ICH (2004). Comparability of Biotechnological/Biological Products Subject to Changes in their Manufacturing Process, Q5E.
The European Parliament and Council (2001). Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use.
P. L. Martin, P. J. Bugelski, Br. J. Pharmacol., 166, 806 – 822 (2012).
E. J. Gribble, P. V. Sivakumar, R. A. Ponce, S. D. Hughes, Expert Opin. Drug Metab. Toxicol., 3, 209 – 324 (2007).
ICH (2011). Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals, S6(R1).
ICH (1999). Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, Q6B.
US FDA (2010). Non-Inferiority Clinical Trials (Draft Guidance).
Biosimilars: design and analysis of follow-on biologics, , Chapman & Hall/CRC biostatistics series, 60, Shein-Chung Chow (2013).
S. K. Tse, J. Y. Chang, W. L. Su, et al., J. Biopharm. Stat., 16, 861 – 874 (2006).
P. A. Lachenbruch, W Rida, and J. Kou, J. Biopharm. Stat., 14, 275 – 290 (2004).
The CONSORT statement. http://www.consort-statement.org/index.aspx?o=1011. Accessed December 10, 2007.
EMA (2014). Publication of clinical reports: EMA adopts landmark policy to take effect on 1 January 2015.
ICH (1998). Statistical Principles for Clinical Trials, E9.
US FDA (2007). Computerized Systems Used in Clinical Investigations.
Design and Analysis of Bioavailability and Bioequivalence Studies, 3rd ed., Chapman & Hall/CRC, Shein-Chung Chow (2009).
Council of Europe. European Pharmacopoeia, Strasbourg, Council of Europe (2014).
United States Pharmacopeia and National Formulary (USP 37-NF 32), Vol 39(4), MD: United States Pharmacopeia Convention, Rockville, 2014:111 (2014).
DOI: https://doi.org/10.30906/0869-2092-2015-78-6-37-44
Ссылки
- На текущий момент ссылки отсутствуют.
© Издательский дом «Фолиум», 1993–2022
Наши партнеры:
Наши издания: | Подписаться на наши издания Вы можете через почтовые каталоги агентства «Роспечать» и Объединенный каталог «Пресса России», а также на сайтах агентств «УП Урал Пресс», «Информнаука», «Прессинформ» и «Профиздат» | Адрес pедакции: Москва, Дмитровское ш., 157, корп. 6 Тел.: +7 499 258-08-28, доб. 18 E-mail: ekf@folium.ru |